Funding for this research was provided by:
Received: 5 October 2020
Accepted: 24 January 2021
First Online: 30 January 2021
Ethics approval and consent to participate
: The study protocol (reference number AG8689) was submitted to the Western Institutional Review Board, and an ethics waiver was provided as it was determined that ethics approval was not required for this study. All data were collected following procedures with ethics committee approval, including obtaining the informed consent of patients, and data were fully de-identified prior to receipt by Adelphi Real World. Patients were presented with written details of the study, how their data would be used, and indicated written consent via a write-in check box. Participation was voluntary.
: Not applicable.
: AT and EP are employees of Sunovion Pharmaceuticals Inc. (Marlborough, Massachusetts, USA). EJ, JP, JW, and AG are employees of Adelphi Real World (Manchester, UK).